stoxline Quote Chart Rank Option Currency Glossary
Applied Therapeutics, Inc. (APLT)
5.35  0.26 (5.11%)    07-23 16:00
Open: 5.05
High: 5.44
Volume: 830,065
Pre. Close: 5.09
Low: 5.02
Market Cap: 611(M)
Technical analysis
2024-07-23 4:50:26 PM
Short term     
Mid term     
Targets 6-month :  7.07 1-year :  8.26
Resists First :  6.05 Second :  7.07
Pivot price 5.15
Supports First :  4.91 Second :  4.19
MAs MA(5) :  5.3 MA(20) :  5
MA(100) :  5.17 MA(250) :  3.56
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  51.5 D(3) :  54.1
RSI RSI(14): 56.8
52-week High :  9.39 Low :  1.17
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ APLT ] has closed below upper band by 39.5%. Bollinger Bands are 6.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.44 - 5.48 5.48 - 5.51
Low: 4.95 - 4.98 4.98 - 5.02
Close: 5.29 - 5.35 5.35 - 5.4
Company Description

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Headline News

Thu, 18 Jul 2024
Applied Therapeutics (NASDAQ:APLT) Given Outperform Rating at Royal Bank of Canada - Defense World

Tue, 16 Jul 2024
Susquehanna Portfolio Strategies LLC Trims Stake in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World

Tue, 16 Jul 2024
Applied Therapeutics, Inc. (NASDAQ:APLT) Sees Large Growth in Short Interest - MarketBeat

Mon, 01 Jul 2024
Applied Therapeutics Added to Russell 3000® Index - StockTitan

Sat, 29 Jun 2024
Why Is Applied Therapeutics, Inc. (APLT) the Best Biotech Penny Stock to Buy Now? - Yahoo Finance

Wed, 29 May 2024
Applied Therapeutics: Strong Buy With AT-007 Nearing Approval For Galactosemia (APLT) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 114 (M)
Held by Insiders 8.075e+007 (%)
Held by Institutions 5.9 (%)
Shares Short 4,280 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -7.477e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -11 %
Return on Assets (ttm) 101.5 %
Return on Equity (ttm) -51.6 %
Qtrly Rev. Growth -477000 %
Gross Profit (p.s.) -49.35
Sales Per Share -307.71
EBITDA (p.s.) 0
Qtrly Earnings Growth -2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -67 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 18.04
Stock Dividends
Dividend 0
Forward Dividend 6.32e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android